Franceschini Davide, Teriaca Maria Ausilia, Dominici Luca, Franzese Ciro, Scorsetti Marta
Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Cancer Manag Res. 2021 Sep 7;13:7009-7031. doi: 10.2147/CMAR.S294116. eCollection 2021.
Oligometastatic patients are a heterogeneous and yet not well-defined population. The actual definition identifies as oligometastatic, patients with 1-5 metastases in 1-3 different organs. However, only a proportion of these patients are "true" oligometastatic and therefore derive some kinds of benefit from local ablative approaches like stereotactic ablative radiation therapy (SABR). Since SABR is an easily accessible, effective and well-tolerated treatment, it is widely employed in the oligometastatic scenarios, without a particular focus on selection criteria. However, it should be crucial to identify predictive and prognostic features that could be clinically implemented. Therefore, we conducted this narrative review of the available literature to summarize all clinical, radiomic, genetic and epigenetic features found to be predictive of overall survival, progression-free survival or local control of oligometastatic patients treated with SABR.
寡转移患者是一个异质性且定义尚不明确的群体。实际定义将在1 - 3个不同器官中有1 - 5个转移灶的患者认定为寡转移患者。然而，这些患者中只有一部分是“真正的”寡转移患者，因此能从立体定向消融放疗（SABR）等局部消融方法中获得某种益处。由于SABR是一种易于获取、有效且耐受性良好的治疗方法，它在寡转移情况下被广泛应用，而没有特别关注选择标准。然而，识别可在临床上应用的预测和预后特征至关重要。因此，我们对现有文献进行了这项叙述性综述，以总结所有已发现的可预测接受SABR治疗的寡转移患者总生存期、无进展生存期或局部控制情况的临床、影像组学、基因和表观遗传特征。
